- Piramal Pharma has acquired an additional 40.67% stake in Hyderabad-based CDMO Yapan Bio for ₹76 crore ($7.95 million), taking its total ownership to 74%.
- The transaction expands Piramal Pharma’s large-molecule capabilities and strengthens its ADCelerate platform for antibody-drug conjugate development.
Piramal Pharma Ltd. has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics. The ₹76 crore ($7.95 million) transaction, finalized on August 18, 2026, increases Piramal Pharma’s ownership of Yapan Bio to 74%, making the company a subsidiary.
Yapan Bio will continue to operate within Piramal Pharma Solutions (PPS), the CDMO arm of Piramal Pharma. The company said the transaction will integrate Yapan Bio’s large-molecule capabilities into its broader service offering and expand its ability to develop and scale complex biologic therapies.
The acquisition also supports PPS’s ADCelerate platform, a fixed-price integrated service designed to support Phase I antibody-drug conjugate (ADC) development from R&D to GMP manufacturing in as little as 12 months. Piramal Pharma said Yapan Bio’s capabilities will further support the platform and its ADC services.
The transaction is part of Piramal Pharma’s strategy to expand its presence in biologics and broaden its services for customers developing complex therapies. The company said integrating Yapan Bio’s expertise into its global network will support demand for biologics and access to therapies.
“By integrating Yapan Bio’s specialized expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.”
Peter DeYoung, CEO, Piramal Global Pharma
